Mainstream Media Claim: A CBD nose spray could soon deliver fast seizure control for children with Dravet syndrome and Lennox-Gastaut syndrome.

Primary Journal Data: The article is a narrative translational review, not a pediatric clinical trial. It summarizes preclinical studies of nanostructured lipid carrier CBD showing improved brain exposure, higher brain-to-plasma distribution, and anticonvulsant activity in animal seizure models such as pentylenetetrazol-induced convulsions. It reports no enrolled Dravet or Lennox-Gastaut patients, no randomized pediatric efficacy endpoint, and no long-term pediatric nasal safety dataset.

Dr. Caplan’s Clinical Verdict: The concept is scientifically credible and worth formal testing, but it is not ready for clinical substitution of approved oral CBD or standard antiseizure regimens. Families should hear this as a promising delivery hypothesis, not as an available, proven treatment.

Study Overview: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental epileptic encephalopathies that appear in early childhood, are unresponsive to medications, and have a dismal neurodevelopmental prognosis. Most patients do not respond well to polytherapy, and the need to fulfill this gap in clinical practice is urgent. Cannabidiol (CBD) has proven to be an effective adjunct drug, but oral preparations have low bioavailability, slow onset and systemic adverse effects. Nanostructured lipid carriers (NLCs) are an innovative therapeutic technology that can deliver CBD directly to the brain via the nose, enhance brain targeting, achieve faster onset, and minimize systemic exposure, which could be a valuable solution to current deficiencies in treatment.Intranasal NLC-CBD has preclinical evidence of increasing brain CBD levels, facilitating anticonvulsant action, and protecting against seizures in established animal models, like pentylenetetrazol-induced convulsions. NLC-based preparations have increased brain-to-plasma ratios and longer central exposure at lower doses in comparison to free or orally administered CBD. Despite these promising findings, there are still translational gaps to be addressed, such as insufficient safety data in the long term, disease-specific DS/LGS genetic models, inconsistencies in the pediatric nasal physiology, and conventional clinical dosing paradigms.Literature for this review was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, covering studies published up to March 2026 on CBD, NLC, intranasal drug delivery, DS, and LGS.There is a dire need to carry out properly designed clinical trials that would demonstrate the safety, pharmacokinetics (PK) and efficacy of intranasal NLC-CBD in DS and LGS. The first pediatric clinical trials, adaptive trial models and regulatory harmonization are necessary to convert this noble nanomedicine approach into a clinical therapy. Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare and severe forms of epilepsy which often start in childhood. A significant number of patients fail to respond to several antiseizure drugs, and have recurrent seizures. Cannabidiol (CBD) is a chemical found in the cannabis plant that is effective in reducing seizures, but there are some limitations in oral CBD products, including slow absorption and inconsistent efficacy and the possibility for drug interaction. In this review, a novel delivery system of delivering CBD to the brain via a nose spray containing nanostructured lipid carriers (NLCs) is investigated. The use of these tiny lipid-based particles can aid in the delivery of CBD to the brain more rapidly and effectively, avoiding the digestion process and lowering first-pass metabolism. Consequently, intranasal NLC-CBD is likely to have a quicker onset of effect, better brain penetration, and reduced doses. This review provides a summary of existing preclinical evidence, as well as safety and regulatory considerations and outlines the possible clinical development options for this technology. It also underscores some of the future possibilities, such as the application of artificial intelligence (AI), novel clinical trial designs, and combination therapies. While additional clinical trials are necessary, intranasal NLC-CBD is a promising approach for better seizure control, quality of life and treatment ease for DS and LGS patients and their caregivers.

Primary Source & Scope: Published in Therapeutic delivery (2026Sep17) conducted by Yashika, Sachin Yadav, Anish Arora, Nisha Bharti et al.. Primary Source Link | Primary Record: DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849

Clinical research into Nanostructured lipid carriers for intranasal canna is progressing through rigorously documented peer-reviewed cohorts.

Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries.

This paper is clinically interesting because it focuses on a problem that epilepsy clinicians and families recognize immediately. Oral cannabidiol can be helpful in Dravet syndrome and Lennox-Gastaut syndrome, but its pharmacology is not elegant: variable absorption, food effects, hepatic metabolism, and interactions can complicate care in children already taking multiple antiseizure medications. A nasal lipid nanoparticle formulation that improves brain targeting and reduces systemic exposure would be a meaningful advance if it can be made reproducible, tolerable, and clinically effective.

The caution is equally important. Dravet and Lennox-Gastaut syndromes are not generic seizure disorders, and animal convulsion models cannot substitute for disease-specific pediatric trials. Before this technology can influence practice, it needs stepwise evidence: formulation stability, nasal mucosal safety, pediatric pharmacokinetics, interaction studies, and randomized seizure outcomes using accepted endpoints such as convulsive seizure frequency or drop seizure frequency. For now, it is a rational research direction, not a prescribing roadmap.

Three Rules for Critical Reading